Ethical and human subject burdens of trials conducted to evaluate biosimilars

Jennifer A. Ohn, Preston J. Atteberry, Mark R. Trusheim, Peter B. Bach
doi: https://doi.org/10.1101/2021.03.05.21252938

Article Information

doi 
https://doi.org/10.1101/2021.03.05.21252938
History 
  • March 9, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Jennifer A. Ohn, MPH1,*,
  2. Preston J. Atteberry, MD2,
  3. Mark R. Trusheim, MSc3 and
  4. Peter B. Bach, MD, MAPP1
  1. 1Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY
  2. 2Department of Medicine, NewYork Presbyterian Hospital, New York, NY
  3. 3Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA
  1. ↵*Corresponding Author:
    Jennifer A. Ohn, MPH, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY, jennaohn{at}gmail.com
Back to top
Posted March 09, 2021.
Download PDF
Data/Code
Email
Ethical and human subject burdens of trials conducted to evaluate biosimilars
Jennifer A. Ohn, Preston J. Atteberry, Mark R. Trusheim, Peter B. Bach
medRxiv 2021.03.05.21252938; doi: https://doi.org/10.1101/2021.03.05.21252938
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area